Drug intelligence / Profile preview

Cloxyquin

Development stage: Preclinical
Modality: Small Molecules

Overview

Cloxyquin, also known as 5-chloro-8-hydroxyquinoline, is a small molecule with antimicrobial, antifungal, and antiprotozoal properties. It has been studied for its activity against bacteria, fungi, and protozoa, including strains of *Mycobacterium tuberculosis*. Cloxyquin acts by chelating metal ions, which disrupts microbial growth. Additionally, it activates the peroxisome proliferator-activated receptor gamma (PPARγ) and is a novel activator of the two-pore domain potassium channel TRESK, which is linked to migraines and pain sensitivity.

Brand names: DermofonginDermofungin
Other names: 5-Chloro-8-hydroxyquinolineCloxiquinaCloxiquineCloxiquinum5-Chloroquinolin-8-olMonochlorohydroxyquinoline

Targets

KCNK18 (TWIK-related spinal cord potassium channel)

Beyond the preview

Go deeper on Cloxyquin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Cloxyquin.

Explore the full profile